Notorious OxyContin-maker Purdue Pharma—which has been widely criticized for deceptively marketing its highly addictive painkiller and for its role in spurring the current nationwide epidemic of opioid abuse and overdose deaths—is moving ahead with a new, potent drug, one said to be an antidote to opioid overdoses.
Source: After pushing addictive OxyContin, Purdue now pursuing overdose antidote | Ars Technica
From 2007 to 2018, the Sacklers paid themselves more than $4B from opioid sales.
Source: Here’s what the Sacklers didn’t want you to see in the OxyContin lawsuit | Ars Technica
Family that runs Purdue also runs Rhodes Pharma—and patented an addiction drug.
Source: Mega-rich family behind opioid crisis has second, secret opioid company | Ars Technica